B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma

Abstract Talquetamab recently received approval for relapsed refractory multiple myeloma. However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab. Herein, we present the outcome of 10 patients who received BCMA based therapies fol...

Full description

Bibliographic Details
Published in:eJHaem
Main Authors: Asis Shrestha, Marah Alzubi, Jawad Alrawabdeh, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits vanRhee, Samer Al Hadidi
Format: Article
Language:English
Published: Wiley 2024-06-01
Subjects:
BCMA
bispecific antibodies
CAR‐T therapy
GPRC5D
multiple myeloma
sequencing
Online Access:https://doi.org/10.1002/jha2.896

Internet

https://doi.org/10.1002/jha2.896

Similar Items